Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL402 Target Snapshot

3-hydroxy-3-methylglutaryl-coenzyme A reductase · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
1,334Compounds
138Assays
16Approved Drugs
2,069.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

3-hydroxy-3-methylglutaryl-coenzyme A reductase shows approved-linked disease relevance led by Hypercholesterolemia. 5 more disease programs remain visible in the same review block. 8 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P04035. Start with Hypercholesterolemia, then reuse UniProt P04035 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with Hypercholesterolemia, then reuse UniProt P04035 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 8 linked drugs
Open source guide
Disease program
Hypercholesterolemia

3-hydroxy-3-methylglutaryl-coenzyme A reductase shows approved-linked disease relevance led by Hypercholesterolemia. 5 more disease programs remain visible in the same review block. 8 linked drugs remain visible in the same block.

Start review with Hypercholesterolemia because it currently carries approved-linked support. Linked drugs include ATORVASTATIN CALCIUM, FLUVASTATIN SODIUM, LOVASTATIN, PITAVASTATIN CALCIUM. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 8 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats 3-hydroxy-3-methylglutaryl-coenzyme A reductase as ChEMBL target CHEMBL402, mapped to UniProt P04035. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
3-hydroxy-3-methylglutaryl-coenzyme A reductase
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL402
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P04035
3-hydroxy-3-methylglutaryl-coenzyme A reductase
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether 3-hydroxy-3-methylglutaryl-coenzyme A reductase is the right protein anchor across sources, using UniProt P04035 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why Hypercholesterolemia is currently framed as approved-linked support. It currently carries 8 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred Name3-hydroxy-3-methylglutaryl-coenzyme A reductase
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP04035
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein Label3-hydroxy-3-methylglutaryl-coenzyme A reductase
UniProt AccessionP04035
Component TypeProtein
Sequence Length888 aa

3-hydroxy-3-methylglutaryl-coenzyme A reductase

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as 3-hydroxy-3-methylglutaryl-coenzyme A reductase, mapped to UniProt P04035. Sequence length is 888 aa.

Mapped IDP04035
Review name3-hydroxy-3-methylglutaryl-coenzyme A reductase
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

3-hydroxy-3-methylglutaryl-coenzyme A reductase shows approved-linked disease relevance led by Hypercholesterolemia. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
Hypercholesterolemia
8 linked drugs · 8 direct · 8 efficacy
Linked drugATORVASTATIN CALCIUM
Linked drugFLUVASTATIN SODIUM
Linked drugLOVASTATIN
Linked drugPITAVASTATIN CALCIUM
Approved-linked Approved
familial hypercholesterolemia
6 linked drugs · 6 direct · 6 efficacy
Linked drugATORVASTATIN CALCIUM
Linked drugFLUVASTATIN SODIUM
Linked drugPITAVASTATIN CALCIUM
Linked drugPRAVASTATIN SODIUM
Approved-linked Approved
hyperlipidemia
6 linked drugs · 6 direct · 6 efficacy
Linked drugATORVASTATIN CALCIUM
Linked drugPITAVASTATIN CALCIUM
Linked drugPITAVASTATIN MAGNESIUM
Linked drugPITAVASTATIN SODIUM
Approved-linked Approved
Abnormal circulating lipid concentration
5 linked drugs · 5 direct · 5 efficacy
Linked drugATORVASTATIN CALCIUM
Linked drugPITAVASTATIN CALCIUM
Linked drugPITAVASTATIN MAGNESIUM
Linked drugPITAVASTATIN SODIUM
Approved-linked Approved
atherosclerosis
4 linked drugs · 4 direct · 4 efficacy
Linked drugLOVASTATIN
Linked drugPRAVASTATIN SODIUM
Linked drugROSUVASTATIN CALCIUM
Linked drugSIMVASTATIN
Approved-linked Approved
cardiovascular disease
4 linked drugs · 4 direct · 4 efficacy
Linked drugATORVASTATIN CALCIUM
Linked drugLOVASTATIN
Linked drugPRAVASTATIN SODIUM
Linked drugSIMVASTATIN
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with Hypercholesterolemia because it currently carries approved-linked support. Linked drugs include ATORVASTATIN CALCIUM, FLUVASTATIN SODIUM, LOVASTATIN, PITAVASTATIN CALCIUM. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseHypercholesterolemia
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

16
Approved
4
Phase II
1
Phase I
Assay Mix

Activity Type Distribution

IC501,149.0
KI846.0
EC5048.0
KD26.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL162642 10.85 IC50 0.014 Preclinical
CHEMBL159951 10.74 IC50 0.018 Preclinical
CHEMBL160102 10.3 IC50 0.05 Preclinical
CHEMBL1477 10.07 IC50 0.085 Approved
CHEMBL2375155 9.97 IC50 0.106 Preclinical
CHEMBL400874 9.7 IC50 0.2 Preclinical
CHEMBL1487 9.64 IC50 0.227 Approved
CHEMBL163277 9.57 IC50 0.27 Preclinical
CHEMBL399773 9.52 IC50 0.3 Preclinical
CHEMBL228955 9.52 IC50 0.3 Preclinical
Distribution

pChEMBL Value Distribution

31
5.0
34
5.5
26
6.0
18
6.5
40
7.0
60
7.5
71
8.0
26
8.5
16
9.0
8
9.5
pChEMBL
Approved Drugs

Approved Drugs

ROSUVASTATIN
CHEMBL1496
Approved 2003
Properties Compare Identifier
CERIVASTATIN
CHEMBL1477
Approved 1997
Properties Compare Identifier
ATORVASTATIN
CHEMBL1487
Approved 1996
Properties Compare Identifier
FLUVASTATIN
CHEMBL2220442
Approved 1993
Properties Compare Identifier
SIMVASTATIN
CHEMBL1064
Approved 1991
Properties Compare Identifier
PRAVASTATIN
CHEMBL1144
Approved 1991
Properties Compare Identifier
PRAVASTATIN SODIUM
CHEMBL690
Approved 1991
Properties Compare Identifier
LOVASTATIN
CHEMBL503
Approved 1987
Properties Compare Identifier
Assay Landscape

Assay Landscape

138
Total Assays
299
Tested Compounds
2
Assay Types
Binding — 133 assays, 299 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 79 207 7.3
cell-based format 53 80 6.8
microsome format 1 12 7.6
Functional — 5 assays, 19 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 2 19 6.7
organism-based format 2 0 —
assay format 1 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine